Analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Repare Therapeutics (RPTX – Research Report), with a price target of $25.00.
Geoff Meacham has given his Buy rating due to a combination of factors including Repare Therapeutics’ recent partnership and promising preclinical results. The company’s collaboration with Debiopharm to investigate the synergy between lunresertib and Debio 0123 in the MYTHIC trial has been a significant point of interest. Lunresertib is a selective and potent oral small molecule inhibitor with anticancer activity, while Debio 0123 is a brain-penetrant and highly selective WEE1 inhibitor. Their combination has shown to synergistically induce DNA damage and tumor regression, with compelling in vivo results that include complete responses in certain cases. Additionally, the ability of this combination to overcome resistance mechanisms further bolsters its therapeutic potential.
Furthermore, the analyst’s enthusiasm is reinforced by a pipeline of upcoming catalysts that could drive the company’s valuation. These include various anticipated clinical trial data releases across different combinations and stages of development. The initiation of clinical trials and the expected data from these trials, such as lunresertib in combination with FOLFIRI and gemcitabine, and the expansion cohort data for lunresertib with camonsertib, represent significant milestones that could potentially validate the company’s approach and support the Buy rating. The sharing of costs under the clinical study and collaboration agreement also highlights a strategic approach to development and financial management.
See the top stocks recommended by analysts >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Repare Therapeutics (RPTX) Company Description:
Repare Therapeutics Inc is a precision oncology company engaged in discovery and development of novel therapeutics. The company use its proprietary, genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Using its SNIPRx platform, it is developing pipeline of SL product candidates, including its product candidate, RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.
Read More on RPTX:
